ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Harold L. Lazar
Yusheng Bao
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lazar, H. L.
Right arrow Articles by Bernard, S. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lazar, H. L.
Right arrow Articles by Bernard, S. A.
Related Collections
Right arrow Myocardial protection

Ann Thorac Surg 2002;73:1522-1527
© 2002 The Society of Thoracic Surgeons

Original article: cardiovascular

Pretreatment with angiotensin-converting enzyme inhibitors attenuates ischemia-reperfusion injury

Harold L. Lazar, MD*a, Yusheng Bao, MDa, Samuel Rivers, BSa, Sheilah A. Bernard, MDa

a Department of Cardiothoracic Surgery, Boston Medical Center and the Boston University School of Medicine, Boston, Massachusetts, USA

Accepted for publication January 22, 2002.

* Address reprint requests to Dr Lazar, Department of Cardiothoracic Surgery, Boston Medical Center, 88 E. Newton St, B404, Boston, MA 02118 USA
e-mail: harold.lazar{at}bmc.org

Background. The Heart Outcomes Prevention Evaluation (HOPE) trial demonstrated that ischemic events are decreased in patients receiving angiotensin-converting enzyme (ACE) inhibitors. This study sought to determine whether pretreatment with ACE inhibitors would attentuate ischemic injury during surgical revascularization of ischemic myocardium.

Methods. In a porcine model, the second and third diagonal vessels were occluded for 90 minutes, followed by 45 minutes of cardioplegic arrest, and 180 minutes of reperfusion. Ten pigs received quinapril (20 mg PO q.d.) for 7 days prior to surgery; 10 others received no-ACE inhibitors.

Results. Quinapril-treated animals required less cardioversions for ventricular arrhythmias (1.58 ± 0.40 vs 2.77 ± 0.22; p < 0.05), had higher wall motion scores assessed by two-dimensional echocardiography (4 = normal to -1 = dyskinesia; 2.11 ± 0.10 vs 1.50 ± 0.07; p < 0.05), more complete coronary artery endothelial relaxation to bradykinin (45% ± 3% vs 7% ± 4%; p < 0.005), and lower infarct size (24.0% ± 3.0% vs 40.0% ± 1.7%; p < 0.0001).

Conclusions. ACE inhibition prior to coronary revascularization enhances myocardial protection by decreasing ventricular irritability, improving regional wall motion, lowering infarct size, and preserving endothelial function.




This article has been cited by other articles:


Home page
 CirculationHome page
H. L. Lazar
All Coronary Artery Bypass Graft Surgery Patients Will Benefit From Angiotensin-Converting Enzyme Inhibitors
Circulation, January 1, 2008; 117(1): 6 - 8.
[Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
H. L. Lazar
Role of Angiotensin-Converting Enzyme Inhibitors in the Coronary Artery Bypass Patient
Ann. Thorac. Surg., March 1, 2005; 79(3): 1081 - 1089.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
H. L. Lazar
Quinaprilat during cardioplegic arrest
J. Thorac. Cardiovasc. Surg., April 1, 2003; 125(4): 974 - 975.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2002 by The Society of Thoracic Surgeons.